Strengthening the reporting of genetic risk prediction studies: The GRIPS statement

Italian Journal of Public Health

Volumn 9, Issue 2, 2012, Pages 115-121

  Janssens, A Cecile J W ^a   Ioannidis, John P A ^b,c,d,e,f   van Duijn, Cornelia M ^a   Little, Julian ^g   Khoury, Muin J ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Genetic risk models; GRIPS

Indexed keywords

EID: 84863469682     PISSN: 17237815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665-74
2. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408-16
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007; 99: 236-43
4. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005; 97: 1043-55
5. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005; 2: 416-22
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007; 43: 2559-79
7. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302: 2345-52
8. von Elm E, Egger M. The scandal of poor epidemiological research. BMJ 2004; 329: 868-9
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40: 35-53
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296
11. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. Ital J Public Health 2009; 6: 238-55
12. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003; 326: 41-4
13. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-72
14. Janssens ACJW, Van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 2009; 1: 20
15. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010; 172: 517-24
16. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009; 338: b606
17. Khoury MJ, Dorman JS. The Human Genome Epidemiology Network. Am J Epidemiol 1998; 148: 1-3
18. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005; 97: 715-23
19. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94
20. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-12
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ital J Public Health 2009; 6: 354-91
22. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: e297
23. Vandenbroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: For whom does the guideline toll? J Clin Epidemiol 2009; 62: 594-6
24. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-35
25. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72
26. Janssens ACJW, Khoury MJ. Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? Circ: Cardiovasc Genet 2010; 3: 3-5